Heart attack

April 24, 2019

Canagliflozin-based Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: Canagliflozin (Brand name: Invokana, Sulisent, Prominad), a Sodium-glucose co-transporter 2 inhibitor used to treat TIIDM, increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes, via up-regulation of its target gene, 24/April/2019, 7.37 am

Introduction: What they say A recent study from the Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel shows that “ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation.” This study was […]
April 22, 2019

Molecular therapy for cardiac dysfunction: Canagliflozin (trade name: Invokana), a medication used to treat hyperglycemia, decreases Mir-29 expression, activates Wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1, and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function, via upregulation of its target gene, 22/April/2018, 10.31 pm

Introduction: What they say:   A recent study from the Institute of Pharmacology and Toxicology, Technical University Munich (TUM), 80802, Munich, Germany; DZHK (German Center for Cardiovascular […]
April 21, 2019

Intracardiac injection of Cyclic helix-B peptide (CHBP) attenuates pathogenesis-associated with Myocardial infarction: Cyclic helix-B peptide (CHBP) decreases IRF3, GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leukocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits ventricular dilation, and promotes heart repair and survival, via up regulation of its target gene, 22/April/2019, 12.07 am

Introduction: What they say:  A recent study from Department of Systems Biology, Harvard Medical School, Boston, Massachusetts, USA; and Cardiovascular Research Center, Massachusetts General Hospital and […]
April 18, 2019

 Intracardiac injection of Cyclic helix B peptide (CHBP) promotes heart regeneration and repair: Intracardiac injection of Cyclic helix B peptide (CHBP) decreases tumor suppressor MiR-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 18/April/2019, 10.55 pm

Introduction: What they say: A recent study from Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA; Key Laboratory […]